People with type 2 diabetes achieve 6% weight loss with liraglutide 3 mg in phase 3a obesity trial
18 March 2013 | By Novo Nordisk
Novo Nordisk announced the headline results from a 56-week, double-blind phase 3a clinical trial...
List view / Grid view
News
Daiichi Sankyo announces positive Phase 3 study results (PRASFIT-ACS) for Prasugrel in Japanese patients with ACS undergoing PCI
16 March 2013 | By Daiichi Sankyo
Results of the PRASFIT-ACS study...
Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
15 March 2013 | By Novartis
First filing for LDK378 anticipated in early 2014...
Lonza and Hyglos reach agreement for endotoxin detection patents
Lonza Walkersville, Inc. and Hyglos GmbH, a German biotech company, announced today that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection.
European Commission approves new pre-treatment options for QUTENZA™ in peripheral neuropathic pain
14 March 2013 | By Pegasus
The EC has approved expanded options for pre-treatment prior to use of QUTENZA...
Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis
13 March 2013 | By Novartis
New data will be presented...
Merck and Luminex Corporation enter agreement
13 March 2013 | By Merck
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for AD...
Biogen Idec submits application to FDA for first long-lasting Factor VIII therapy for hemophilia A
12 March 2013 | By Biogen Idec
“This regulatory submission marks another significant step..."
Antimicrobial resistance poses ‘catastrophic threat’
12 March 2013 | By Department of Health
Chief Medical Officer says global action is needed otherwise in 20 years we could see any one of us dying following minor surgery...
Merck provides update on IMPROVE-IT Trial
12 March 2013 | By Merck
IMPROVE-IT is an 18,141 patient event-driven trial...
American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013
11 March 2013 | By Boehringer Ingelheim
International peer-to-peer sharing...
New data reinforce strong long-term clinical performance of Abbott’s Absorb™ Bioresorbable Vascular Scaffold
11 March 2013 | By Abbott
Abbott announced positive long-term results...
BASF Pharma Callanish production approved by Korean FDA
11 March 2013 | By BASF
BASF Pharma Callanish has received approval to sell concentrated omega-3 fatty acids as active pharmaceutical ingredients...
Catalent announces major China expansion with two new facilities for Softgel Technologies and Clinical Supply Solutions businesses
11 March 2013 | By Catalent Pharma Solutions
Catalent announced two joint ventures...
Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients
11 March 2013 | By Boehringer Ingelheim
New data presented...
